Translational Drug Development (TD2)’s Post

Ovarian cancer affects hundreds of thousands of women around the world, to the extent of nearly 7 cases per 100,000. That's why Wistar researchers like Executive Vice President Dr. David Weiner are working on the basis of next-generation therapeutics to fight ovarian cancer with the power of basic biomedical research. By engineering novel monoclonal antibodies to engage the immune system's natural killer cells against ovarian cancer — a feat achieved by taking advantage of the siglec-7 receptor in collaboration with Wistar's Abdel-Mohsen laboratory — Dr. Weiner's team has demonstrated preclinical efficacy against ovarian cancer tumors. Read more about how Drs. David Weiner and Mohamed Abdel-Mohsen joined forces to make their ovarian-cancer-fighting discovery here: https://bit.ly/3QCdYs9 #worldovariancancerday #ovariancancerday #ovariancancer #cancerresearch

Tumoroid cultures, also known as tumor organoids, are three-dimensional cell culture models that closely mimic the complexity and characteristics of actual tumors. These cultures have the potential to revolutionize various areas of cancer research and treatment by providing more accurate and personalized models for studying tumor biology, drug discovery, and treatment development. Looking forward to this webinar!

🚀 Exciting Clinical Milestone for Eisbach Bio! 🚀 We are thrilled to announce that the first patient has been dosed in our Phase 1/2 MATCH clinical trial of EIS-12656. The cancer trial conducted at The University of Texas MD Anderson Cancer Center, marks a significant step forward in our mission to develop transformative medicines leveraging synthetic lethality. “Our entry into the cancer clinic with the allosteric inhibitor EIS-12656 represents a unique approach in targeting ALC1, offering hope for patients with tumors characterized by impaired DNA damage and repair,” said Adrian Schomburg, Ph.D., Founder and CEO of Eisbach Bio GmbH. “This clinical study will explore EIS-12656’s potential to target specific genetic and molecular vulnerabilities, aiming to deliver a drug that is both efficacious and well-tolerated.” Full press release: https://lnkd.in/eTC65FeW Stay tuned for more updates as we continue our journey to pioneer the frontiers of cancer therapy. 💪 #CancerResearch #ClinicalTrials #Biotechnology #Oncology #SyntheticLethality

#MovingMedicineForward: Congratulations to our friends at #EisbachBio on dosing the first patient in their Phase 1/2 MATCH clinical trial for EIS-12656, a new allosteric inhibitor targeting genetically-defined advanced solid tumors. This study aims to evaluate the safety, tolerability, & efficacy of EIS-12656, with a focus on #Gynecological, #Pancreatic, & #Prostate cancer patients progressing under PARP inhibitor treatment. At CTI, we're proud to collaborate with Eisbach Bio in providing #Regulatory & #ClinicalTrial management services for this #Oncology trial. Together, we’re #AdvancingHealthcareSolutions for those battling advanced cancers. Learn more about this trial in the link below. 

🔬 𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡 𝐱 𝐄𝐒𝐌𝐎 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 𝟐𝟎𝟐𝟒 We look forward to presenting updates for selected assets of our diversified immuno-oncology portfolio at the ESMO - European Society for Medical Oncology Congress 2024 in Barcelona. This year’s presentations feature programs across our multi-platform #oncology toolkit, including #mRNA-based cancer vaccines, targeted therapy approaches such as CAR-T cell therapies and ADCs, and next-generation #immunomodulators. We believe that the future of cancer treatment will be driven by the combination of modalities. Combination therapies have the potential to open up new opportunities through complementary or even synergistic mechanisms of action. Our goal is clear: Establish novel treatment paradigms to address the fundamental challenges of treating #cancer across all stages of the disease and improve outcomes for patients. 🚀 𝐅𝐢𝐧𝐝 𝐨𝐮𝐭 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐨𝐮𝐫 𝐮𝐩𝐝𝐚𝐭𝐞𝐬 𝐭𝐨 𝐛𝐞 𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐞𝐝 𝐚𝐭 #𝐄𝐒𝐌𝐎𝟐𝟒. 👇 𝑹𝒆𝒂𝒅 𝒎𝒐𝒓𝒆: https://lnkd.in/etszNHB8

Inocras CancerVision demonstrates 100% concordance with Illumina’s TSO500 panel—meaning we detect every single variant identified by TSO500, without missing a thing. But CancerVision goes beyond, offering additional insights that only a whole-genome sequencing approach can deliver. This marks a significant leap in comprehensive cancer genomics. #CancerGenomics #WholeGenomeSequencing #PersonalizedMedicine #CancerResearch #OncologyInnovation #PrecisionOncology #CancerDiagnostics #Bioinformatics #ClinicalGenomics #CancerVision #Inocras

👏 Thank you James Clubb for giving an excellent presentation on our promising clinical data on TILT-123 in combination with pembrolizumab for #OvarianCancer at the American Association for Cancer Research (AACR) Annual Meeting 2024 this week in San Diego! James demonstrated our phase 1 trial’s promising preliminary safety and efficacy results for platinum-resistant or refractory ovarian cancer patients, which highlight the potential of TILT-123 as an innovative cancer treatment by altering the tumor microenvironment and bolstering the body's immune response against cancer. We were delighted to see this included by Drug Discovery World in their highlights from #AACR24 piece: https://lnkd.in/e8-2kX36 📝 See the poster: https://lnkd.in/gHguit5C 🔗 Read our press release: https://lnkd.in/gewF3uTn #BioTech #Innovation #Oncology #ClinicalTrial

We're excited to share the significant findings from the recently published CancerVision Target-Enhanced Whole-Genome Sequencing (TE-WGS) study. From a cohort of 49 patients, our CancerVision TE-WGS test detected all 498 variants identified by Illumina’s TSO500 panel, solidifying our technology’s precision as a comprehensive approach in personalized oncology that matches TSO500's key biomarker detection capabilities. CancerVision offers additional, critical clinical actions, and its adaptability and cost-effectiveness underscore its clinical utility in personalized cancer treatment. To read the abstract, visit more: https://lnkd.in/gMAGJyvQ

Hope can go a long way. And for cancer patients and researchers, immuno-oncology is promising. Download our white paper to learn about the evolution of understanding cancer and where we are today with immunotherapies: https://bit.ly/4aICiku #DrugDevelopment #Oncology #ImmunoOncology #CancerResearch

🔊 This September, during Prostate Cancer Awareness Month, Heidelberg Pharma AG stands in solidarity with the millions of men and their families affected by #ProstateCancer.   Prostate cancer is the most common cancer in men, with cases expected to nearly double by 2040.   At #HeidelbergPharma, our mission is to create inspired medicines for those diagnosed with this serious disease to enhance treatment options and survival rate. Our preclinical candidate, HDP-103, a PSMA-ATAC, is specifically designed to target metastatic castration-resistant prostate cancer - a particularly challenging form of the disease.   🔊 Collectively, we can make a difference in the fight against prostate cancer!   #ADCs #ATAC #ProstateCancerMonth #CancerResearch